

# Cataplexy – Pipeline Insight, 2020

<https://marketpublishers.com/r/CF0793B0F8ADEN.html>

Date: November 2020

Pages: 40

Price: US\$ 1,500.00 (Single User License)

ID: CF0793B0F8ADEN

## Abstracts

This report can be delivered to the clients within 48-72 Hours

DelveInsight's, "Cataplexy – Pipeline Insight, 2020," report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Cataplexy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

### Geography Covered

Global coverage

### Cataplexy Understanding

#### Cataplexy: Overview

Cataplexy is characterized by transient episodes of voluntary muscle weakness precipitated by intense emotion. The sudden onset of muscle weakness characterizes cataplexy. Such episodes are transient, lasting seconds to minutes, and get precipitated by intense emotions. Cataplectic attacks are more frequently incited by positive emotions (i.e., laughter, excitement, etc.) than negative emotions (i.e., anger, fear, frustration, etc.), with laughter being the most common precipitant. It is the complete or partial paralysis of voluntary muscles that is responsible for the weakness associated with cataplexy; however, it bears noting that the muscles of eye movement and respiration get spared during these attacks. The suppression of serotonergic and noradrenergic neuronal circuits permit the complete or partial paralysis of voluntary muscles.

## Symptoms

The symptoms of Cataplexy include:

Dropping eyelids

Jaw dropping

Head falling to the side due to neck muscle weakness

Whole body falling to the ground

Various muscles around your body twitching without an obvious cause

## Diagnosis

Diagnosis of cataplexy is carried out by studying sleep (polysomnogram), which records the muscles and brain involved in sleeping. Multiple sleep latency test examines short naps throughout the day to study how quickly the patient's falls asleep during the spacing of naps.

## Treatment

The following pharmacologic agents are considered first-line in the management of cataplexy: Selective serotonin reuptake inhibitors (fluoxetine 10 to 80 mg by mouth daily every morning), norepinephrine reuptake inhibitors (atomoxetine 40 to 80 mg by mouth daily every morning), serotonin/norepinephrine reuptake inhibitors (venlafaxine extended-release 37.5 to 150 mg by mouth once daily every morning), and tricyclic antidepressants (clomipramine 10 to 150 mg by mouth daily every morning). Tricyclic antidepressants (TCAs) have fallen out of favor for the treatment of cataplexy due to their anticholinergic side effects (i.e., delirium, dry mucous membranes, hyperthermia, ileus, mydriasis, tachycardia, and urinary retention). Sodium oxybate, the sodium salt of gamma-hydroxybutyrate has recently got approval from FDA for the treatment of Cataplexy.

## Cataplexy Emerging Drugs Chapters

This segment of the Cataplexy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

### Cataplexy Emerging Drugs

#### FT218: Avadel

FT218 is a drug which is a GABA B receptor agonists. Originally, this compound was owned by Flamel Technologies. FT218 is in Phase 3 of the clinical study and is presently under the development of Avadel. The trial initiated in June 2020 and is expected to complete by June 2022 with 250 enrolled participants. (NCT04451668)

#### AXS12: Axome Therapeutics

AXS12 (Reboxetine) is a Phase 2 drug in development for the treatment of cataplexy. It acts as adrenergic uptake inhibitor and is currently being developed by Axome Therapeutics.

Further product details are provided in the report

### Cataplexy: Therapeutic Assessment

This segment of the report provides insights about the different Cataplexy drugs segregated based on following parameters that define the scope of the report, such as:

#### Major Players in Cataplexy

There are approx. 3+ key companies which are developing the therapies for Cataplexy. The companies which have their Cataplexy drug candidates in the most advanced stage, i.e. phase III include, Avadel.

#### Phases

DelveInsight's report covers around 3+ products under different phases of clinical

development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Cataplexy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

intravitreal

Subretinal

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

### Cataplexy: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Cataplexy therapeutic drugs key players involved in developing key drugs.

### Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cataplexy drugs.

### Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Cataplexy R&D. The therapies under development are focused on novel approaches to treat/improve Cataplexy.

### Cataplexy Report Insights

Cataplexy Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

## Cataplexy Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

## Key Questions

### Current Treatment Scenario and Emerging Therapies:

How many companies are developing Cataplexy drugs?

How many Cataplexy drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Cataplexy?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Cataplexy therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Cataplexy and their status?

What are the key designations that have been granted to the emerging drugs?

## Key Players

Avadel

## Axome Therapeutics

### Key Products

FT218

AXS12

## Contents

- Introduction
- Executive Summary
- Cataplexy: Overview
  - Causes
  - Mechanism of Action
  - Signs and Symptoms
  - Diagnosis
  - Disease Management
- Pipeline Therapeutics
  - Comparative Analysis
- Therapeutic Assessment
  - Assessment by Product Type
  - Assessment by Stage and Product Type
  - Assessment by Route of Administration
  - Assessment by Stage and Route of Administration
  - Assessment by Molecule Type
  - Assessment by Stage and Molecule Type
- Cataplexy – DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
  - Cataplexy companies’ collaborations, Licensing, Acquisition -Deal Value Trends
- Cataplexy Collaboration Deals
  - Company-Company Collaborations (Licensing / Partnering) Analysis
  - Company-University Collaborations (Licensing / Partnering) Analysis
- Late Stage Products (Phase III)
  - Comparative Analysis
- FT218: Avadel
  - Product Description
  - Research and Development
  - Product Development Activities
- Mid Stage Products (Phase II)
  - Comparative Analysis
- AXS12: Axome Therapeutics
  - Product Description
  - Research and Development
  - Product Development Activities
- Drug profiles in the detailed report
- Early Stage Products (Phase I)



Comparative Analysis  
Drug Name: Company Name  
Product Description  
Research and Development  
Product Development Activities  
Drug profiles in the detailed report  
Pre-clinical and Discovery Stage Products  
Comparative Analysis  
Drug Name: Company Name  
Product Description  
Research and Development  
Product Development Activities  
Drug profiles in the detailed report  
Inactive Products  
Comparative Analysis  
Cataplexy Key Companies  
Cataplexy Key Products  
Cataplexy- Unmet Needs  
Cataplexy- Market Drivers and Barriers  
Cataplexy- Future Perspectives and Conclusion  
Cataplexy Analyst Views  
Cataplexy Key Companies  
Appendix

## List Of Tables

### LIST OF TABLES

Table 1 Total Products for Cataplexy

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

## List Of Figures

### LIST OF FIGURES

- Figure 1 Total Products for Cataplexy
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

## I would like to order

Product name: Cataplexy – Pipeline Insight, 2020

Product link: <https://marketpublishers.com/r/CF0793B0F8ADEN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CF0793B0F8ADEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970